Across TCGA pan-cancer cohorts, NMB Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NMB data layer compared with 20 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher NMB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NMB expression acts as an unfavorable survival marker.
ESCA are the cancer types where NMB Mutation most reproducibly stratifies survival.